Skip to main content

Table 2 Median ETDRS letters for the PRN pattern and 3Inj pattern

From: A real-world study of effectiveness of intravitreal bevacizumab and ranibizumab injection for treating retinal diseases in Thailand

ETDRS letters

IVB

n

P-value

IVR

n

P-value

Median baseline VA

(IQR)

Median VA at 6 months

(IQR)

Median baseline VA

(IQR)

Median VA at 6 months

(IQR)

The PRN pattern

68–85 letters

69.95

(69.95–76.20)

85.00

(80.15–85.00)

13

0.0013*

69.95

(69.95–69.95)

85.00

(85.00–85.00)

1

**

53–67 letters

57.80

(54.90–61.14)

69.95

(69.95–76.20)

84

0.0000*

56.35

(54.90–58.88)

69.95

(67.52–69.95)

4

0.0679

38–52 letters

46.09

(41.25–50.05)

60.08

(54.90–65.10)

98

0.0000*

46.09

(43.67–50.05)

62.54

(57.80–69.95)

8

0.0116*

23–37 letters

35.00

(35.00–35.00)

54.90

(50.15–65.10)

99

0.0000*

35.00

(29.87–35.00)

54.90

(50.05–65.10)

6

0.0277*

0–22 letters

0.00

(0.00–0.00)

35.00

(19.95–54.90)

241

0.0000*

0.00

(0.00–4.90)

57.80

(57.80–59.97)

13

0.0016*

The 3Inj pattern

68–85 letters

76.20

(69.95–76.20)

85.00

(85.00–85.00)

3

0.1025

69.95

(69.95–69.95)

85.00

(85.00–85.00)

1

**

53–67 letters

60.08

(54.90–61.14)

69.95

(69.95–80.15)

15

0.0006*

59.97

(59.97–59.97)

69.95

(69.95–69.95)

1

**

38–52 letters

46.09

(45.21–50.05)

65.10

(60.08–69.95)

22

0.0000*

46.09

(46.09–46.09)

65.10

(65.10–65.10)

1

**

23–37 letters

35.00

(35.00–35.00)

60.03

(54.90–69.95))

37

0.0000*

32.43

(29.87–35.00)

67.53

(65.10–69.95)

2

0.1797

0–22 letters

0.00

(0.00–0.00)

50.05

(35.00–57.80)

1

**

0.00

(0.00–0.00)

65.10

(0.00–69.95)

3

0.1655

  1. * P-value < 0.05, ** Not enough samples to test for VA improvement
  2. ETDRS Early Treatment Diabetic Retinopathy Study; IQR Interquartile range; n Number of patients; VA Visual Acuity